Details:
The company has signed an agreement to acquire five legacy brands are Piclin, Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor) catering to gastroenterology, urology and anti-infective segments.
Lead Product(s): Sodium Picosulfate
Therapeutic Area: Gastroenterology Product Name: Piclin
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: $12.1 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 22, 2023
Details:
Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company's Mytesi® drug product to Cardinal Health for the period of August 11, 2020 through September 3, 2020.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Oasis Capital
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Agreement September 10, 2020